CRTX News and Press, Cortexyme Inc. From 08/14/20

- Open label extension is currently active for GAIN Trial completers in the United States with robust conversion of eligible patients - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollme...

Presentations to be webcast on Cortexyme’s website Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief execu...

Bristol Myers Squibb resubmits multiple myeloma therapy application Bristol Myers Squibb ( BMY ) announced that it has resubmitted its application for ide-cel, a cell therapy targeting blood cancer multiple myeloma. The company had initially filed the application in May, but the FDA refu...

Cortexyme ( CRTX -0.5% ) announces encouraging preclinical data on lead candidate atuzaginstat (COR388) that, it says, support its potential for treating cardiovascular disease (CVD) and Alzheimer's disease (AD). The data are being presented at the Alzheimer's Association International C...

-- Presentation to be webcast on Cortexyme’s website Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Stephen Dominy, M.D., the company’s ...

-- Researchers presented new preclinical data on atuzaginstat and the potential impact on cardiovascular disease and AD-associated neurodegeneration in two poster presentations at AAIC 2020 -- Cortexyme also presented phase 1b clinical data demonstrating atuzaginstat‘s thera...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases will be the subject of three research abstracts at the Alzheimer’s Association Inte...

Introduction Through Week 26 of 2020, the Premium Portfolio has gained +14.43%, substantially leading the S&P 500 benchmark by +21.29%. These returns were achieved by actively trading in 11 fewer weeks (nearly halted for an entire quarter) using the alerts of the Momentum Gauge™ t...

Welcome to the ten-year anniversary edition of Insider Weekends. Little did we know that we would end up publishing this series of articles continuously for 10 years when we introduced Insider Weekends on June 13, 2010. In many ways, these days feel a lot like it did in mid-2010 but there are ...